MORGAN STANLEY - BROOKLYN IMMUNOTHERAPEUTICS ownership

BROOKLYN IMMUNOTHERAPEUTICS's ticker is BTX and the CUSIP is 114082100. A total of 62 filers reported holding BROOKLYN IMMUNOTHERAPEUTICS in Q1 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.

Quarter-by-quarter ownership
MORGAN STANLEY ownership history of BROOKLYN IMMUNOTHERAPEUTICS
ValueSharesWeighting
Q3 2022$3,000
-85.7%
13,561
-66.0%
0.00%
Q2 2022$21,000
-98.6%
39,900
-94.5%
0.00%
Q1 2022$1,492,000
-34.3%
727,599
+33.5%
0.00%
Q4 2021$2,271,000
+2241.2%
544,881
+5177.3%
0.00%
Q3 2021$97,000
-67.6%
10,325
-37.7%
0.00%
Q2 2021$299,00016,5840.00%
Other shareholders
BROOKLYN IMMUNOTHERAPEUTICS shareholders Q1 2022
NameSharesValueWeighting ↓
Cypress Point Wealth Management, LLC 471,878$8,499,0006.04%
BALDWIN BROTHERS LLC/MA 44,116$795,0000.09%
DOWLING & YAHNKE LLC 15,806$285,0000.02%
INVERNESS COUNSEL LLC /NY/ 13,307$240,0000.01%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 15,000$270,0000.01%
Cutler Group LLC / CA 4,200$75,0000.00%
MetLife Investment Management, LLC 10,805$194,5980.00%
HAP Trading, LLC 13,900$64,0000.00%
METROPOLITAN LIFE INSURANCE CO/NY 8,272$148,9790.00%
Ameritas Investment Partners, Inc. 1,867$34,0000.00%
View complete list of BROOKLYN IMMUNOTHERAPEUTICS shareholders